FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> celiac disease | ImmusanT | Nexvax2
Syndicate content

Celiac disease vax has positive Ph1 results

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Sufferers from celiac disease may get a reprieve from their gluten-free diets thanks to a vaccine currently in Phase I trials. But the vaccine won't go into Phase II until next year at the earliest, and most likely won't be available to the public until 2017.

In an Australian study, patients receiving weekly doses of ImmusanT's Nexvax2 while on a strict gluten-free diet showed symptoms similar to those of eating gluten. Scientists say this shows they are targeting the right peptides that could help sufferers eventually tolerate gluten.

"The gluten free diet is very difficult, it's costly, it's complex," said Dr. Jason Tye-Din to Dietsinreview. "Unfortunately even people who follow it very well--there's a large proportion who still don't get full healing of their bowel, so alternatives to the gluten free diet are really needed at the moment."

Researchers hope the vaccine will enter Phase II trials early next year, and they believe the vaccine could treat up to 90 percent of celiac disease patients.

- check out the release
- and here's more from the International Business Times

Related Articles:
Mouse-human study IDs celiac disease triggers
VCs invest $21.5M in Alvine's celiac drug program

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Comments (2) | Post a comment
More stories about celiac disease   ImmusanT   Nexvax2  


Do they expect it to also help people who have severe sensitivities to gluten or just persons who have been diagnosed with celiac disease?

You raise a key point, since there are many more people with gluten sensitivity that with a fully-diagnosed case of celiac. The current research increasingly points to a spectrum of conditions ranging from gluten sensitivity to celiac disease. My take on this is that "gluten sensitivity" is quite distinct from celiac, involving the "innate" immune sustems, so I would not expect the "vaccine" to affect this.
I have a couple of blog posts addressing this topic, and would appreciate your comments:

Post a comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.